Concepts (253)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Hepatocellular | 41 | 2024 | 390 | 12.450 |
Why?
|
| Liver Neoplasms | 43 | 2024 | 754 | 11.640 |
Why?
|
| Liver Transplantation | 34 | 2024 | 1177 | 8.200 |
Why?
|
| Chemoembolization, Therapeutic | 8 | 2024 | 35 | 3.000 |
Why?
|
| Bile Duct Neoplasms | 8 | 2024 | 90 | 2.870 |
Why?
|
| Cholangiocarcinoma | 7 | 2024 | 76 | 2.720 |
Why?
|
| Hepatitis C, Chronic | 9 | 2024 | 91 | 2.500 |
Why?
|
| Antiviral Agents | 13 | 2024 | 475 | 2.340 |
Why?
|
| Gastroenterology | 6 | 2024 | 144 | 2.190 |
Why?
|
| Liver Cirrhosis | 13 | 2024 | 254 | 1.730 |
Why?
|
| Liver Diseases | 4 | 2024 | 242 | 1.730 |
Why?
|
| Transplants | 2 | 2023 | 41 | 1.680 |
Why?
|
| Gastroenterologists | 2 | 2023 | 31 | 1.610 |
Why?
|
| Liver Diseases, Alcoholic | 4 | 2024 | 19 | 1.430 |
Why?
|
| Sofosbuvir | 4 | 2017 | 9 | 1.390 |
Why?
|
| Hepatitis C | 4 | 2022 | 170 | 1.350 |
Why?
|
| Radiosurgery | 3 | 2020 | 280 | 1.280 |
Why?
|
| Fatty Liver | 3 | 2023 | 95 | 1.280 |
Why?
|
| Liver | 4 | 2024 | 1205 | 1.250 |
Why?
|
| Humans | 81 | 2024 | 89063 | 1.130 |
Why?
|
| Bile Ducts, Intrahepatic | 6 | 2023 | 72 | 1.050 |
Why?
|
| Blood Coagulation Disorders | 2 | 2024 | 66 | 0.970 |
Why?
|
| Tissue and Organ Procurement | 5 | 2023 | 345 | 0.960 |
Why?
|
| End Stage Liver Disease | 5 | 2024 | 60 | 0.950 |
Why?
|
| Adenoma, Liver Cell | 1 | 2024 | 3 | 0.940 |
Why?
|
| Focal Nodular Hyperplasia | 1 | 2024 | 10 | 0.940 |
Why?
|
| Hepatitis B, Chronic | 3 | 2024 | 32 | 0.930 |
Why?
|
| Hemangioma | 1 | 2024 | 64 | 0.900 |
Why?
|
| Ribavirin | 2 | 2016 | 40 | 0.900 |
Why?
|
| Viral Load | 4 | 2017 | 145 | 0.890 |
Why?
|
| Yttrium Radioisotopes | 8 | 2024 | 58 | 0.870 |
Why?
|
| Cysts | 1 | 2024 | 106 | 0.860 |
Why?
|
| Brachytherapy | 2 | 2021 | 121 | 0.860 |
Why?
|
| Simeprevir | 3 | 2016 | 4 | 0.810 |
Why?
|
| Hepatitis, Viral, Human | 1 | 2022 | 23 | 0.810 |
Why?
|
| Committee Membership | 1 | 2021 | 4 | 0.790 |
Why?
|
| Hemostatics | 1 | 2022 | 57 | 0.790 |
Why?
|
| alpha-Fetoproteins | 4 | 2023 | 43 | 0.790 |
Why?
|
| Career Mobility | 1 | 2021 | 31 | 0.770 |
Why?
|
| Societies, Scientific | 1 | 2021 | 43 | 0.760 |
Why?
|
| Neoadjuvant Therapy | 1 | 2024 | 373 | 0.750 |
Why?
|
| Ablation Techniques | 1 | 2020 | 36 | 0.730 |
Why?
|
| Transplant Recipients | 3 | 2024 | 137 | 0.690 |
Why?
|
| Leadership | 1 | 2021 | 138 | 0.690 |
Why?
|
| Organ Transplantation | 1 | 2023 | 275 | 0.690 |
Why?
|
| Faculty, Medical | 1 | 2021 | 185 | 0.670 |
Why?
|
| Hepacivirus | 4 | 2022 | 129 | 0.650 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2022 | 173 | 0.650 |
Why?
|
| Endosonography | 1 | 2019 | 98 | 0.620 |
Why?
|
| Societies, Medical | 2 | 2021 | 570 | 0.610 |
Why?
|
| Catheter Ablation | 1 | 2020 | 252 | 0.610 |
Why?
|
| Living Donors | 8 | 2023 | 339 | 0.600 |
Why?
|
| Fluorenes | 1 | 2017 | 6 | 0.590 |
Why?
|
| Practice Guidelines as Topic | 1 | 2024 | 1043 | 0.580 |
Why?
|
| Pancreas | 1 | 2019 | 244 | 0.580 |
Why?
|
| Neuroendocrine Tumors | 1 | 2019 | 117 | 0.560 |
Why?
|
| Virus Activation | 1 | 2016 | 41 | 0.560 |
Why?
|
| Embolization, Therapeutic | 3 | 2024 | 262 | 0.550 |
Why?
|
| Molecular Targeted Therapy | 1 | 2019 | 285 | 0.550 |
Why?
|
| Benzimidazoles | 1 | 2017 | 111 | 0.540 |
Why?
|
| Hepatectomy | 3 | 2024 | 170 | 0.530 |
Why?
|
| Peritonitis | 1 | 2015 | 29 | 0.520 |
Why?
|
| Microspheres | 4 | 2024 | 108 | 0.520 |
Why?
|
| Ascites | 1 | 2015 | 56 | 0.510 |
Why?
|
| Catheters, Indwelling | 1 | 2015 | 113 | 0.490 |
Why?
|
| Drainage | 1 | 2015 | 162 | 0.480 |
Why?
|
| Treatment Outcome | 18 | 2024 | 8203 | 0.480 |
Why?
|
| Retrospective Studies | 19 | 2024 | 9003 | 0.480 |
Why?
|
| Liver Failure | 1 | 2014 | 67 | 0.470 |
Why?
|
| Neoplasms | 2 | 2023 | 3035 | 0.470 |
Why?
|
| Drug Therapy, Combination | 5 | 2017 | 783 | 0.470 |
Why?
|
| Bacterial Infections | 1 | 2015 | 184 | 0.460 |
Why?
|
| Middle Aged | 19 | 2024 | 25863 | 0.440 |
Why?
|
| Pancreatic Neoplasms | 1 | 2019 | 666 | 0.430 |
Why?
|
| Tumor Burden | 3 | 2024 | 308 | 0.430 |
Why?
|
| Neoplasm Staging | 3 | 2024 | 2001 | 0.400 |
Why?
|
| United States | 14 | 2024 | 6955 | 0.400 |
Why?
|
| Hepatitis, Alcoholic | 2 | 2022 | 16 | 0.390 |
Why?
|
| Logistic Models | 5 | 2017 | 1212 | 0.390 |
Why?
|
| Male | 21 | 2024 | 42251 | 0.370 |
Why?
|
| Interferon-alpha | 1 | 2010 | 226 | 0.350 |
Why?
|
| Immunosuppressive Agents | 2 | 2016 | 975 | 0.330 |
Why?
|
| Female | 20 | 2024 | 46011 | 0.330 |
Why?
|
| Bariatric Surgery | 2 | 2017 | 195 | 0.310 |
Why?
|
| Polyethylene Glycols | 1 | 2010 | 358 | 0.310 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2024 | 1363 | 0.300 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2008 | 52 | 0.300 |
Why?
|
| Surveys and Questionnaires | 3 | 2023 | 2612 | 0.280 |
Why?
|
| Probiotics | 1 | 2008 | 88 | 0.280 |
Why?
|
| Bevacizumab | 2 | 2024 | 287 | 0.270 |
Why?
|
| Radiopharmaceuticals | 2 | 2024 | 193 | 0.260 |
Why?
|
| Guanine | 2 | 2016 | 207 | 0.260 |
Why?
|
| Hepatitis B virus | 2 | 2015 | 43 | 0.250 |
Why?
|
| Aged | 13 | 2024 | 19077 | 0.250 |
Why?
|
| Fatty Liver, Alcoholic | 1 | 2024 | 6 | 0.250 |
Why?
|
| Hepatitis B Vaccines | 1 | 2024 | 16 | 0.240 |
Why?
|
| Hepatitis B | 2 | 2015 | 75 | 0.240 |
Why?
|
| Paracentesis | 1 | 2024 | 10 | 0.240 |
Why?
|
| Ultrasonography | 2 | 2024 | 711 | 0.240 |
Why?
|
| Primary Prevention | 1 | 2024 | 81 | 0.230 |
Why?
|
| Delphi Technique | 1 | 2024 | 92 | 0.230 |
Why?
|
| Lactulose | 1 | 2023 | 22 | 0.220 |
Why?
|
| Hepatic Encephalopathy | 1 | 2023 | 39 | 0.220 |
Why?
|
| Early Detection of Cancer | 2 | 2020 | 415 | 0.220 |
Why?
|
| Disease-Free Survival | 2 | 2024 | 1214 | 0.220 |
Why?
|
| Employment | 1 | 2023 | 53 | 0.220 |
Why?
|
| Incidence | 3 | 2024 | 1592 | 0.210 |
Why?
|
| Long-Term Care | 1 | 2023 | 61 | 0.210 |
Why?
|
| Risk Factors | 7 | 2024 | 5466 | 0.210 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2024 | 485 | 0.210 |
Why?
|
| Hemostasis | 1 | 2022 | 21 | 0.210 |
Why?
|
| RNA, Viral | 2 | 2016 | 314 | 0.210 |
Why?
|
| Alcoholism | 1 | 2024 | 178 | 0.210 |
Why?
|
| Hepatitis, Chronic | 1 | 2022 | 5 | 0.210 |
Why?
|
| Liver Cirrhosis, Alcoholic | 1 | 2022 | 21 | 0.200 |
Why?
|
| Transgender Persons | 1 | 2024 | 105 | 0.200 |
Why?
|
| Prospective Studies | 4 | 2023 | 4273 | 0.200 |
Why?
|
| Women, Working | 1 | 2021 | 7 | 0.200 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2024 | 967 | 0.200 |
Why?
|
| Genotype | 2 | 2017 | 1848 | 0.200 |
Why?
|
| Sustained Virologic Response | 2 | 2019 | 5 | 0.190 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2015 | 859 | 0.190 |
Why?
|
| Adult | 12 | 2024 | 26507 | 0.190 |
Why?
|
| Liver Function Tests | 1 | 2020 | 92 | 0.180 |
Why?
|
| Infusions, Intra-Arterial | 1 | 2020 | 36 | 0.180 |
Why?
|
| Physicians, Women | 1 | 2021 | 56 | 0.180 |
Why?
|
| Disease Progression | 2 | 2024 | 1488 | 0.180 |
Why?
|
| Hepatic Artery | 1 | 2021 | 84 | 0.180 |
Why?
|
| Education, Medical, Graduate | 1 | 2024 | 390 | 0.180 |
Why?
|
| Time Factors | 6 | 2024 | 5320 | 0.170 |
Why?
|
| Graft Survival | 4 | 2021 | 898 | 0.170 |
Why?
|
| Diagnosis, Differential | 1 | 2024 | 1591 | 0.170 |
Why?
|
| Heart Transplantation | 2 | 2023 | 716 | 0.170 |
Why?
|
| Transaminases | 1 | 2019 | 33 | 0.160 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2019 | 25 | 0.160 |
Why?
|
| Recurrence | 3 | 2024 | 1140 | 0.160 |
Why?
|
| Alkaline Phosphatase | 1 | 2019 | 132 | 0.160 |
Why?
|
| Radiotherapy | 1 | 2020 | 331 | 0.160 |
Why?
|
| Young Adult | 4 | 2024 | 6288 | 0.160 |
Why?
|
| Postoperative Care | 1 | 2019 | 229 | 0.160 |
Why?
|
| Patient Care Planning | 1 | 2019 | 83 | 0.160 |
Why?
|
| Antineoplastic Agents | 2 | 2020 | 2411 | 0.160 |
Why?
|
| Education, Medical | 1 | 2021 | 243 | 0.160 |
Why?
|
| Kidney Transplantation | 2 | 2023 | 849 | 0.150 |
Why?
|
| Positron-Emission Tomography | 1 | 2020 | 336 | 0.150 |
Why?
|
| Adolescent | 4 | 2024 | 9237 | 0.150 |
Why?
|
| Infant | 1 | 2024 | 3147 | 0.150 |
Why?
|
| Internal Medicine | 1 | 2021 | 355 | 0.150 |
Why?
|
| Graft Rejection | 1 | 2023 | 1064 | 0.150 |
Why?
|
| Obesity | 2 | 2017 | 966 | 0.150 |
Why?
|
| Child, Preschool | 1 | 2024 | 3717 | 0.150 |
Why?
|
| Tenofovir | 1 | 2016 | 9 | 0.140 |
Why?
|
| Intestine, Small | 1 | 2019 | 299 | 0.140 |
Why?
|
| Risk Assessment | 5 | 2021 | 2290 | 0.140 |
Why?
|
| Palliative Care | 1 | 2019 | 263 | 0.140 |
Why?
|
| Curriculum | 1 | 2021 | 567 | 0.140 |
Why?
|
| Students, Medical | 1 | 2021 | 418 | 0.130 |
Why?
|
| Hypertension, Portal | 1 | 2016 | 46 | 0.130 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2023 | 266 | 0.130 |
Why?
|
| Pandemics | 1 | 2021 | 771 | 0.120 |
Why?
|
| Genomics | 1 | 2020 | 761 | 0.120 |
Why?
|
| Coinfection | 1 | 2015 | 61 | 0.120 |
Why?
|
| Multivariate Analysis | 2 | 2015 | 988 | 0.120 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2015 | 116 | 0.120 |
Why?
|
| Doxorubicin | 1 | 2015 | 298 | 0.120 |
Why?
|
| Cohort Studies | 3 | 2016 | 2863 | 0.110 |
Why?
|
| Immunotherapy | 3 | 2024 | 669 | 0.110 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2024 | 2552 | 0.110 |
Why?
|
| Prognosis | 2 | 2020 | 3773 | 0.110 |
Why?
|
| Graft vs Host Disease | 1 | 2016 | 360 | 0.110 |
Why?
|
| Biomarkers | 1 | 2020 | 1755 | 0.110 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2016 | 237 | 0.110 |
Why?
|
| Child | 1 | 2024 | 7149 | 0.110 |
Why?
|
| Donor Selection | 2 | 2023 | 74 | 0.100 |
Why?
|
| Aged, 80 and over | 5 | 2024 | 6777 | 0.100 |
Why?
|
| Internship and Residency | 1 | 2021 | 1041 | 0.100 |
Why?
|
| Tissue Donors | 1 | 2015 | 490 | 0.100 |
Why?
|
| Consensus | 2 | 2024 | 356 | 0.100 |
Why?
|
| North America | 2 | 2023 | 184 | 0.090 |
Why?
|
| Attitude | 2 | 2023 | 130 | 0.090 |
Why?
|
| Alcohol Drinking | 2 | 2024 | 273 | 0.090 |
Why?
|
| Anti-Bacterial Agents | 2 | 2023 | 786 | 0.090 |
Why?
|
| Waiting Lists | 2 | 2024 | 183 | 0.090 |
Why?
|
| Calcineurin Inhibitors | 1 | 2009 | 53 | 0.080 |
Why?
|
| Recombinant Proteins | 1 | 2010 | 1012 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2019 | 2657 | 0.080 |
Why?
|
| Protein Kinases | 1 | 2009 | 213 | 0.080 |
Why?
|
| Lactobacillus plantarum | 1 | 2008 | 4 | 0.080 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2009 | 185 | 0.080 |
Why?
|
| Saccharomyces | 1 | 2008 | 21 | 0.080 |
Why?
|
| Antibodies | 1 | 2009 | 353 | 0.070 |
Why?
|
| Metabolic Syndrome | 1 | 2008 | 121 | 0.070 |
Why?
|
| Quality of Life | 1 | 2015 | 1662 | 0.070 |
Why?
|
| Chicago | 1 | 2010 | 1423 | 0.070 |
Why?
|
| Gender Dysphoria | 1 | 2024 | 9 | 0.060 |
Why?
|
| Hypertrophy | 1 | 2024 | 67 | 0.060 |
Why?
|
| International Normalized Ratio | 1 | 2024 | 39 | 0.060 |
Why?
|
| Liver Regeneration | 1 | 2024 | 36 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2008 | 833 | 0.060 |
Why?
|
| Hormone Replacement Therapy | 1 | 2024 | 82 | 0.060 |
Why?
|
| Blood Group Incompatibility | 1 | 2023 | 20 | 0.060 |
Why?
|
| Necrosis | 1 | 2023 | 209 | 0.050 |
Why?
|
| Policy | 1 | 2023 | 35 | 0.050 |
Why?
|
| Bilirubin | 1 | 2023 | 129 | 0.050 |
Why?
|
| Ipilimumab | 1 | 2022 | 61 | 0.050 |
Why?
|
| Capecitabine | 1 | 2022 | 98 | 0.050 |
Why?
|
| Albumins | 1 | 2023 | 129 | 0.050 |
Why?
|
| Propensity Score | 1 | 2022 | 147 | 0.050 |
Why?
|
| Retreatment | 1 | 2021 | 108 | 0.050 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2022 | 170 | 0.050 |
Why?
|
| Survival Rate | 2 | 2015 | 1889 | 0.050 |
Why?
|
| Cisplatin | 1 | 2022 | 617 | 0.050 |
Why?
|
| Informed Consent | 1 | 2023 | 275 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2024 | 424 | 0.040 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2020 | 64 | 0.040 |
Why?
|
| Patient Preference | 1 | 2021 | 108 | 0.040 |
Why?
|
| Prevalence | 1 | 2024 | 1240 | 0.040 |
Why?
|
| Career Choice | 1 | 2021 | 148 | 0.040 |
Why?
|
| Comorbidity | 2 | 2017 | 948 | 0.040 |
Why?
|
| Protective Factors | 1 | 2019 | 23 | 0.040 |
Why?
|
| Educational Measurement | 1 | 2021 | 231 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2021 | 369 | 0.040 |
Why?
|
| Healthcare Disparities | 1 | 2024 | 410 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2021 | 848 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2022 | 1710 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2016 | 3657 | 0.040 |
Why?
|
| Canada | 1 | 2019 | 208 | 0.040 |
Why?
|
| Adiposity | 1 | 2017 | 76 | 0.040 |
Why?
|
| Risk Reduction Behavior | 1 | 2017 | 96 | 0.040 |
Why?
|
| Hepatitis B e Antigens | 1 | 2016 | 7 | 0.030 |
Why?
|
| Patient Selection | 1 | 2020 | 682 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2021 | 1149 | 0.030 |
Why?
|
| Weight Loss | 1 | 2017 | 225 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2021 | 780 | 0.030 |
Why?
|
| Lamivudine | 1 | 2015 | 13 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 2020 | 643 | 0.030 |
Why?
|
| Hepatitis B Core Antigens | 1 | 2015 | 9 | 0.030 |
Why?
|
| Hepatitis B Antibodies | 1 | 2015 | 15 | 0.030 |
Why?
|
| Health Status | 1 | 2017 | 370 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2017 | 771 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2015 | 682 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2014 | 216 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2015 | 461 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 1067 | 0.020 |
Why?
|
| Mice | 1 | 2023 | 11737 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2008 | 171 | 0.020 |
Why?
|
| Age Distribution | 1 | 2008 | 200 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2008 | 233 | 0.020 |
Why?
|
| Probability | 1 | 2008 | 353 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2017 | 2275 | 0.020 |
Why?
|
| Animals | 1 | 2023 | 27317 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2008 | 1796 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2008 | 1837 | 0.010 |
Why?
|